J Clin Oncol: The effect of tislelizumab in second-line treatment of advanced/metastatic esophageal squamous cell carcinoma

In 2020, esophageal cancer (EC) remained the seventh most common cancer worldwide and the sixth leading cause of cancer-related death

The prognosis of metastatic ESCC is currently poor, with a 5-year survival rate of only 5.

This study, an open-label phase 3 trial, enrolled patients with advanced or metastatic ESCC whose tumors had progressed after first-line systemic therapy and were randomized (1:1) to receive the anti-PD-1 antibody tislelizumab Antibiotics (200 mg/3 weeks) or chemotherapy (investigator's choice paclitaxel, docetaxel, or irinotecan)

All patients in the tislelizumab group had significantly longer overall survival compared to the chemotherapy group All patients in the tislelizumab group had significantly longer overall survival compared to the chemotherapy group

In all patients, tislelizumab treatment was associated with higher objective response rates (20.

Compared with chemotherapy, tislelizumab as a second-line therapy can significantly prolong the overall survival of patients with advanced or metastatic esophageal squamous cell carcinoma with good safety

Original source:

Original Source: Original Source:

Lin Shen, et al.

Lin Shen, et al.
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Journal of Clinical Oncology.
April 20, 2022.
https://ascopubs.
org/doi/full/10.
1200/JCO.
21.
01926.


Leave a message here